Medical Device News Magazine

Trinity Life Sciences Institutes a Formal Cell and Gene Therapy Center of Excellence

COE Provides Deep Strategic Expertise and Analytical Capabilities to Support Cell and Gene Therapy Organizations Across the Value Chain

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces a Cell & Gene Therapy (C&GT) Center of Excellence (COE) that supports life sciences companies in successfully commercializing a C&GT asset. The unique challenges and opportunities in commercializing C&GT are markedly different from traditional one-size-fits-all products, requiring innovation and a change in the traditional commercial model.

To enable true commercialization optimization in the C&GT space, there are several areas with C&GT nuances that need to be considered:

  • Operational Model Efficiencies
  • Specialized Manufacturing & Supply Chain Logistics
  • Market Access Complexity
  • Unique Go-To-Market Strategies
  • Patient Centricity
  • Life Cycle Management

Trinity’s C&GT COE provides global partnership to life sciences companies and other service providers in the value chain through advisory services powered by a dedicated team of experts with extensive C&GT commercialization and disease area expertise. Clients are able to leverage expert support and analytical depth, no matter where they are in the commercialization journey. Advisory project examples include:

– Comprehensive situation analysis as a foundation for a gene therapy

– Launch management activities in preparation to commercialize a cell therapy product

– Opportunity evaluation and business development decision support for gene therapies

– Understanding of current market dynamics, potential peak share and value drivers for a novel product

– Modeling of potential Health Care Professionals (HCP) uptake, pricing opportunities and size of the eligible populations for a gene therapy forecast

– And much more

“Trinity is patient first—and every challenge in C&GT commercialization has the added impetus of patients waiting for life-changing therapies,” explains Herman Sanchez, Chief Business Officer at Trinity Life Sciences. “Understanding and resolving those problems have become table stakes with C&GT assets. As these treatments may be curative or first on the market, that work is especially meaningful and impactful.”

“After years of experiencing industry challenges firsthand while commercializing gene therapies, I understand the value of strategic partners who are experienced in C&GT and have supported manufacturers along the challenges commercialization presents,” explained Keren Shani, Executive Director and Head of Cell & Gene Therapy at Trinity Life Sciences. “Trinity launched the C&GT COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.”

A new white paper, Empowering Cancer Immunotherapy: Unleashing the Potential of NK Cell Therapies in Oncology, delivers an overarching assessment of the Natural Killer (NK) cell therapy space with a background on NK-based technology, current clinical development—and ultimately, the value proposition NK cell therapies hold in order to equip readers with the necessary knowledge to drive informed decision-making and potential investment in the space.

Life sciences executives can access the white paper here.

An on-demand webinar, Gene Therapy Uptake: The Elephant in the Room, evaluates the factors that are unique to forecasting gene therapy markets and discusses what companies need to know to maximize their revenue potential. Among other topics, viewers will hear potential pricing strategies to consider—as well as key market drivers and product factors contributing to gene therapy opportunity.

Life sciences executives can view the webinar here.

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.